Why Pharmaceutical Penny Stocks Just Aren't Worth the Risk

In this edition of The Motley Fool's "Ask a Fool" series, Motley Fool One analyst Jason Moser and Motley Fool Stock Advisor analyst Brendan Mathews take a question from a reader who asks: "Based on a tip from a friend's hairdresser, I invested in a pharmaceutical penny stock. In a short time, I've made multiples of my original investment. I've taken my original investment off the table, but I'm going to let the gains ride. What do you think of my plan?"

Brendan explains the difference between a good process and a good outcome using a baseball analogy. Clearly, this is a situation of a bad process (i.e., taking a penny stock tip from a friend's hairdresser) with a good outcome (the investment has generated huge returns so far) -- that happens in investing, baseball and many other areas of life. Brendan goes on to point out the dangers of investing in penny stocks -- most penny stocks don't work out well for investors. Jason seconds Brendan's opinion on the dangers of penny stocks, and he points out the uncertainty involved in small pharma stocks. Without knowing the details of this specific penny stock, both Brendan and Jason are skeptical of continuing to hold it, even if it's generated good returns so far.

Boost your 2014 returns with The Motley Fool's top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

The article Why Pharmaceutical Penny Stocks Just Aren't Worth the Risk originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story